About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

M&A markets don't like volatility and unpredictability, and what we've seen in the past few weeks is the opposite of that,” ...

Mitsubishi Chemical Group Corp. (MCG; Tokyo) announced that it has decided to transfer its consolidated subsidiary Mitsubishi Tanabe Pharma Corp. (MTPC; ...

Bain's latest acquisition follows a string of hefty investments the private equity firm has made in Japan in recent months.

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...